The Manila Times

Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer

Nanjing Leads Biolabs Co., Ltd. ('Leads Biolabs' or the 'Company,' Stock Code: 9887.HK) announced on March 6, 2026 that the ...
Yahoo Finance

Global Development Accelerates: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Granted Fast Track Designation by FDA

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: "With Opamtistomig now receiving Fast Track Designation from the FDA—following Breakthrough Therapy Designation in China and Orphan ...
The New England Journal of Medicine

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC), with increased activity in tumors that ...
ascopubs.org

Adverse events profile of novel agents targeting immune checkpoints beyond PD-1/PD-L1 and CTLA-4 in solid tumors: A meta-analysis.

First-in-human study of ZGGS15, a dual-specific antibody targeting LAG-3 and TIGIT, as monotherapy in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Mena FN

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Dosed First Patient In New Indication, Paving A New Immunotherapy Pathway For TNBC Patients

(MENAFN- GetNews) Nanjing, China - February 10, 2026 - Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the“Company,” Stock Code: 9887) today announced that the first patient has been successfully ...